GlaxoSmithKline And Human Genome Sciences Announce Initiation Of Phase 3 Clinical Trial Of Lymphostat-B® In Systemic Lupus Erythematosus
Sun, 18 Feb 2007 08:00 AM EST
... GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the initiation of dosing in BLISS-76, one of two pivotal Phase 3 clinical trials of LymphoStat-B® (belimumab) in patients with active systemic lupus erythematosus (SLE). [click link for full article] ...
Related Topics
- Clinical Trials
- Systemic Lupus Erythematosus
- Lupus
- Genes and Gene Therapy
- Systemic Lupus Erythematosus/sle
- Cutaneous Lupus Erythematosus
- Drug-induced lupus erythematosus
- Psychopharmacology
- Lupus Anticoagulant
- Systemic Lupus
- Human Genome Epidemiology Network
- Scleroderma
- Human Papilloma Virus
- Lupus Nephritis
- Growth Hormones
- Growth Hormone
- Pharmacology
- Human Papillomavirus
- Trastuzumab
- Tarceva

Not Signed In -
